[Our experience in the treatment of gastroduodenal hemorrhage with somatostatin].
Somatostatin, a pituitary hormone with an inhibitory action on gastric secretion, has improved the therapeutic approach to the treatment of the hemorrhagic complications accompanying gastroduodenal ulcer. The authors report on their experience "in doppio cieco" with 84 patients, 53 of whom treated with somatostatin and 31 with cimetidine, the respective success rates being 96.6% and 90.32% in the two treatment groups. It was also noted that the somatostatin-treated group showed earlier arrest of hemorrhage and a lower blood transfusion requirement.